Qualitest Recalls Children's Acetaminophen Suspension for Assay Failure
Qualitest Pharmaceuticals is recalling Children's Q-PAP Acetaminophen Oral Suspension because the product failed an assay test at the 12-month timepoint.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The source text explicitly labels the issue as a 'Superpotent Drug' recall, which involves a significant deviation from the intended drug strength. Per the rubric, significant injury or property damage reports, or high-risk deviations like superpotency, align with a Severe (4) classification, especially given the FDA Class II designation which implies potential for temporary or reversible harm.
Plain-English summary
Qualitest Pharmaceuticals is initiating a recall of Children's Q-PAP, Acetaminophen, Oral Suspension, Bubble Gum Flavor. The product is an over-the-counter liquid medication containing 160 mg of acetaminophen per 5 mL, distributed nationwide in 4 FL OZ (118 mL) bottles.
The recall was initiated due to a failure of the product assay at the 12-month timepoint. The source text identifies this as a "Superpotent Drug" issue, indicating the medication may contain higher levels of the active ingredient than intended. The recall covers specific lot codes: L049J12A, L067M12A, L079B13A, L079B13B, L077E13A, L010H13A, L011J13A, and L101K13A.
Consumers should check their bottles for the affected lot codes and stop using the product if it matches. The FDA has classified this as a Class II recall, which means the product may cause temporary or medically reversible health problems, or where the probability of serious adverse health consequences is remote.
The recalled product
- Product
- CHILDREN'S Q-PAP, Acetaminophen, ORAL SUSPENSION, BUBBLE GUM FLAVOR, Active ingredient (in each 5 mL = 1 tsp) Acetaminophen USP 160 mg, 4 FL OZ (118 mL), Made in the USA for Qualitest Pharmaceuticals, Huntsville, AL 35811, NDC 0603-0841-54, OTC
- Manufacturer
- Qualitest Pharmaceuticals
- Affected units
- 181,908
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (8)
- Codes: L049J12A
- L067M12A
- L079B13A
- L079B13B
- L077E13A
- L010H13A
- L011J13A
- L101K13A
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by Qualitest Pharmaceuticals under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · Qualitest Pharmaceuticals
See all →- LowQualitest Recalls Allopurinol Tablets Due to Oversized and Discolored Appearance
FDA (Drugs) · 2015-09-09
- LowQualitest Recalls HydrOXYzine Tablets Due to Unreadable Identification Codes
FDA (Drugs) · 2015-07-22
- ModerateQualitest Recalls Disulfiram Tablets Due to Dissolution Failure
FDA (Drugs) · 2015-07-08
- LowQualitest Recalls Promethazine VC With Codeine Syrup Due to Impurity
FDA (Drugs) · 2015-04-15
- ModerateQualitest Recalls Promethazine DM Syrup Due to Plastic Particulates
FDA (Drugs) · 2015-03-18
Same hazard · superpotency
See all →- HighAripiprazole 10 mg tablets recalled after testing superpotent in one lot
FDA (Drugs) · 2025-09-24
- ModerateHYDROmorphone Hydrochloride 50 mg Cassettes Recalled for Superpotency
FDA (Drugs) · 2025-04-30
- HighLevothyroxine Sodium Tablets Recalled Nationwide for Potency Variance
FDA (Drugs) · 2024-12-18
- HighLevothyroxine Sodium Tablets Recalled for Subpotent and Superpotent Content
FDA (Drugs) · 2024-12-18
- ModerateTriamcinolone Acetonide Cream USP Recalled for Out-of-Specification Potency Variance
FDA (Drugs) · 2024-11-27